We also demonstrate a co‐dependency of TSG101 and BRCA1/2 for the survival of breast cancer cells, similar to the synthetic lethality observed for PARP inhibitor olaparib and BRCA1/2 deficiency. Here, TSG101 is linked to breast cancer.